Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 papers


  Bacterial Infections and Mycoses

  Free Subscription

Articles published in PLoS Med

Retrieve available abstracts of 61 articles:
HTML format

Single Articles

    May 2020
  1. BROGER T, Nicol MP, Szekely R, Bjerrum S, et al
    Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data.
    PLoS Med. 2020;17:e1003113.
    PubMed     Abstract available

  2. DEO S, Singh S, Jha N, Arinaminpathy N, et al
    Predicting the impact of patient and private provider behavior on diagnostic delay for pulmonary tuberculosis patients in India: A simulation modeling study.
    PLoS Med. 2020;17:e1003039.
    PubMed     Abstract available

    February 2020
  3. LIENHARDT C, Nunn A, Chaisson R, Vernon AA, et al
    Advances in clinical trial design: Weaving tomorrow's TB treatments.
    PLoS Med. 2020;17:e1003059.
    PubMed     Abstract available

    January 2020
  4. DEAN AS, Zignol M, Cabibbe AM, Falzon D, et al
    Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data.
    PLoS Med. 2020;17:e1003008.
    PubMed     Abstract available

  5. SULIS G, Pai M
    Isoniazid-resistant tuberculosis: A problem we can no longer ignore.
    PLoS Med. 2020;17:e1003023.
    PubMed     Abstract available

    December 2019
  6. VERNON A, Fielding K, Savic R, Dodd L, et al
    The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials.
    PLoS Med. 2019;16:e1002884.
    PubMed     Abstract available

  7. LEE EC, Azman AS, Kaminsky J, Moore SM, et al
    The projected impact of geographic targeting of oral cholera vaccination in sub-Saharan Africa: A modeling study.
    PLoS Med. 2019;16:e1003003.
    PubMed     Abstract available

    October 2019
  8. BROWNE SH, Umlauf A, Tucker AJ, Low J, et al
    Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial.
    PLoS Med. 2019;16:e1002891.
    PubMed     Abstract available

  9. BRIGDEN G, Nhung NV, Skrahina A, Ndjeka N, et al
    Advances in clinical trial design for development of new TB treatments-Translating international tuberculosis treatment guidelines into national strategic plans: Experiences from Belarus, South Africa, and Vietnam.
    PLoS Med. 2019;16:e1002896.

  10. XU Y, Cancino-Munoz I, Torres-Puente M, Villamayor LM, et al
    High-resolution mapping of tuberculosis transmission: Whole genome sequencing and phylogenetic modelling of a cohort from Valencia Region, Spain.
    PLoS Med. 2019;16:e1002961.
    PubMed     Abstract available

    September 2019
  11. AIBANA O, Huang CC, Aboud S, Arnedo-Pena A, et al
    Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis.
    PLoS Med. 2019;16:e1002907.
    PubMed     Abstract available

  12. LIENHARDT C, Vernon AA, Cavaleri M, Nambiar S, et al
    Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.
    PLoS Med. 2019;16:e1002915.
    PubMed     Abstract available

    July 2019
  13. SCHUTZ C, Barr D, Andrade BB, Shey M, et al
    Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study.
    PLoS Med. 2019;16:e1002840.
    PubMed     Abstract available

  14. DOOLEY KE, Hanna D, Mave V, Eisenach K, et al
    Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.
    PLoS Med. 2019;16:e1002842.

  15. PENN-NICHOLSON A, Hraha T, Thompson EG, Sterling D, et al
    Correction: Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.
    PLoS Med. 2019;16:e1002880.
    PubMed     Abstract available

  16. OLLIARO PL, Vaillant M
    Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness.
    PLoS Med. 2019;16:e1002850.
    PubMed     Abstract available

  17. DAVIES G, Boeree M, Hermann D, Hoelscher M, et al
    Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.
    PLoS Med. 2019;16:e1002851.
    PubMed     Abstract available

  18. CHOI YH, Andrews N, Miller E
    Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study.
    PLoS Med. 2019;16:e1002845.
    PubMed     Abstract available

    June 2019
  19. CAMPBELL JR, Dowdy D, Schwartzman K
    Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries.
    PLoS Med. 2019;16:e1002824.
    PubMed     Abstract available

  20. Correction: Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation.
    PLoS Med. 2019;16:e1002823.
    PubMed     Abstract available

  21. CHIAVENNA C, Presanis AM, Charlett A, de Lusignan S, et al
    Estimating age-stratified influenza-associated invasive pneumococcal disease in England: A time-series model based on population surveillance data.
    PLoS Med. 2019;16:e1002829.
    PubMed     Abstract available

  22. HERNANDEZ-SANTIAGO V, Davey PG, Nathwani D, Marwick CA, et al
    Changes in resistance among coliform bacteraemia associated with a primary care antimicrobial stewardship intervention: A population-based interrupted time series study.
    PLoS Med. 2019;16:e1002825.
    PubMed     Abstract available

  23. KIRBY MA, Nagel CL, Rosa G, Zambrano LD, et al
    Effects of a large-scale distribution of water filters and natural draft rocket-style cookstoves on diarrhea and acute respiratory infection: A cluster-randomized controlled trial in Western Province, Rwanda.
    PLoS Med. 2019;16:e1002812.
    PubMed     Abstract available

    May 2019
  24. LALVANI A, Berrocal-Almanza LC, Halliday A
    Predicting progression to active tuberculosis: A rate-limiting step on the path to elimination.
    PLoS Med. 2019;16:e1002814.
    PubMed     Abstract available

  25. KLEIN K, Bernachea MP, Iribarren S, Gibbons L, et al
    Correction: Evaluation of a social protection policy on tuberculosis treatment outcomes: A prospective cohort study.
    PLoS Med. 2019;16:e1002826.
    PubMed     Abstract available

    April 2019
  26. GUPTA-WRIGHT A, Corbett EL, Wilson D, van Oosterhout JJ, et al
    Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: Derivation and external validation cohort study.
    PLoS Med. 2019;16:e1002776.
    PubMed     Abstract available

  27. STRYDOM N, Gupta SV, Fox WS, Via LE, et al
    Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
    PLoS Med. 2019;16:e1002773.
    PubMed     Abstract available

  28. KAWASAKI M, Echiverri C, Raymond L, Cadena E, et al
    Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts.
    PLoS Med. 2019;16:e1002780.
    PubMed     Abstract available

  29. PENN-NICHOLSON A, Hraha T, Thompson EG, Sterling D, et al
    Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.
    PLoS Med. 2019;16:e1002781.
    PubMed     Abstract available

  30. CHURCHYARD GJ, Swindells S
    Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB.
    PLoS Med. 2019;16:e1002787.
    PubMed     Abstract available

  31. WARSINSKE H, Vashisht R, Khatri P
    Host-response-based gene signatures for tuberculosis diagnosis: A systematic comparison of 16 signatures.
    PLoS Med. 2019;16:e1002786.
    PubMed     Abstract available

  32. VEKEMANS J, O'Brien KL, Farrar J
    Tuberculosis vaccines: Rising opportunities.
    PLoS Med. 2019;16:e1002791.
    PubMed     Abstract available

  33. MANJALY THOMAS ZR, Satti I, Marshall JL, Harris SA, et al
    Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    PLoS Med. 2019;16:e1002790.
    PubMed     Abstract available

  34. COLMAN RE, Mace A, Seifert M, Hetzel J, et al
    Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation.
    PLoS Med. 2019;16:e1002794.
    PubMed     Abstract available

  35. KLEIN K, Bernachea MP, Irribarren S, Gibbons L, et al
    Evaluation of a social protection policy on tuberculosis treatment outcomes: A prospective cohort study.
    PLoS Med. 2019;16:e1002788.
    PubMed     Abstract available

  36. GARCIA-PRATS AJ, Schaaf HS, Draper HR, Garcia-Cremades M, et al
    Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
    PLoS Med. 2019;16:e1002789.
    PubMed     Abstract available

  37. HATHERILL M, Chaisson RE, Denkinger CM
    Addressing critical needs in the fight to end tuberculosis with innovative tools and strategies.
    PLoS Med. 2019;16:e1002795.
    PubMed     Abstract available

  38. HANRAHAN CF, Nonyane BAS, Mmolawa L, West NS, et al
    Contact tracing versus facility-based screening for active TB case finding in rural South Africa: A pragmatic cluster-randomized trial (Kharitode TB).
    PLoS Med. 2019;16:e1002796.
    PubMed     Abstract available

    March 2019
  39. MABUD TS, de Lourdes Delgado Alves M, Ko AI, Basu S, et al
    Correction: Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil.
    PLoS Med. 2019;16:e1002764.
    PubMed     Abstract available

  40. PHILLIPS PPJ, Mitnick CD, Neaton JD, Nahid P, et al
    Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.
    PLoS Med. 2019;16:e1002767.
    PubMed     Abstract available

  41. LIENHARDT C, Nahid P
    Advances in clinical trial design for development of new TB treatments: A call for innovation.
    PLoS Med. 2019;16:e1002769.
    PubMed     Abstract available

  42. BRADY OJ, Osgood-Zimmerman A, Kassebaum NJ, Ray SE, et al
    The association between Zika virus infection and microcephaly in Brazil 2015-2017: An observational analysis of over 4 million births.
    PLoS Med. 2019;16:e1002755.
    PubMed     Abstract available

    February 2019
  43. SUBBARAMAN R, Nathavitharana RR, Mayer KH, Satyanarayana S, et al
    Constructing care cascades for active tuberculosis: A strategy for program monitoring and identifying gaps in quality of care.
    PLoS Med. 2019;16:e1002754.
    PubMed     Abstract available

  44. WEI X, Zhang Z, Hicks JP, Walley JD, et al
    Long-term outcomes of an educational intervention to reduce antibiotic prescribing for childhood upper respiratory tract infections in rural China: Follow-up of a cluster-randomised controlled trial.
    PLoS Med. 2019;16:e1002733.
    PubMed     Abstract available

    January 2019
  45. MABUD TS, de Lourdes Delgado Alves M, Ko AI, Basu S, et al
    Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil.
    PLoS Med. 2019;16:e1002737.
    PubMed     Abstract available

    September 2018
  46. SUTHAR AB, Moonan PK, Alexander HL
    Towards national systems for continuous surveillance of antimicrobial resistance: Lessons from tuberculosis.
    PLoS Med. 2018;15:e1002658.
    PubMed     Abstract available

  47. KWAN A, Daniels B, Saria V, Satyanarayana S, et al
    Variations in the quality of tuberculosis care in urban India: A cross-sectional, standardized patient study in two cities.
    PLoS Med. 2018;15:e1002653.
    PubMed     Abstract available

    August 2018
  48. MCINTOSH AI, Jenkins HE, White LF, Barnard M, et al
    Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis.
    PLoS Med. 2018;15:e1002638.
    PubMed     Abstract available

    July 2018
  49. ALIPANAH N, Jarlsberg L, Miller C, Linh NN, et al
    Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies.
    PLoS Med. 2018;15:e1002595.
    PubMed     Abstract available

  50. HARAUSZ EP, Garcia-Prats AJ, Law S, Schaaf HS, et al
    Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    PLoS Med. 2018;15:e1002591.
    PubMed     Abstract available

    June 2018
  51. COLDIRON ME, Assao B, Page AL, Hitchings MDT, et al
    Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial.
    PLoS Med. 2018;15:e1002593.
    PubMed     Abstract available

    March 2018
  52. PAI M
    Time for high-burden countries to lead the tuberculosis research agenda.
    PLoS Med. 2018;15:e1002544.
    PubMed     Abstract available

    January 2018
  53. DAVIES B, Turner KME, Benfield T, Frolund M, et al
    Pelvic inflammatory disease risk following negative results from chlamydia nucleic acid amplification tests (NAATs) versus non-NAATs in Denmark: A retrospective cohort.
    PLoS Med. 2018;15:e1002483.
    PubMed     Abstract available

    December 2017
  54. KENDALL EA, Schumacher SG, Denkinger CM, Dowdy DW, et al
    Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study.
    PLoS Med. 2017;14:e1002472.
    PubMed     Abstract available

    November 2017
  55. RUDGARD WE, Evans CA, Sweeney S, Wingfield T, et al
    Comparison of two cash transfer strategies to prevent catastrophic costs for poor tuberculosis-affected households in low- and middle-income countries: An economic modelling study.
    PLoS Med. 2017;14:e1002418.
    PubMed     Abstract available

  56. SHETE PB, Dowdy DW
    Measuring success: The challenge of social protection in helping eliminate tuberculosis.
    PLoS Med. 2017;14:e1002419.
    PubMed     Abstract available

  57. YATES TA, Tomlinson LA, Bhaskaran K, Langan S, et al
    Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: A population based cohort.
    PLoS Med. 2017;14:e1002457.
    PubMed     Abstract available

    October 2017
  58. DATTA S, Saunders MJ, Tovar MA, Evans CA, et al
    Improving tuberculosis diagnosis: Better tests or better healthcare?
    PLoS Med. 2017;14:e1002406.
    PubMed     Abstract available

  59. SYLVIA S, Xue H, Zhou C, Shi Y, et al
    Tuberculosis detection and the challenges of integrated care in rural China: A cross-sectional standardized patient study.
    PLoS Med. 2017;14:e1002405.
    PubMed     Abstract available

  60. KEITEL K, Kagoro F, Samaka J, Masimba J, et al
    A novel electronic algorithm using host biomarker point-of-care tests for the management of febrile illnesses in Tanzanian children (e-POCT): A randomized, controlled non-inferiority trial.
    PLoS Med. 2017;14:e1002411.
    PubMed     Abstract available

  61. WHITTLES LK, White PJ, Didelot X
    Estimating the fitness cost and benefit of cefixime resistance in Neisseria gonorrhoeae to inform prescription policy: A modelling study.
    PLoS Med. 2017;14:e1002416.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bacterial Infections and Mycoses is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.